Published in Nucleic Acids Res on July 11, 1990
Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev (1999) 7.76
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev (1996) 3.46
Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol (1998) 3.34
Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J Bacteriol (1992) 3.05
The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun (1999) 2.94
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest (1995) 2.91
Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol (2007) 2.77
Role of novel choline binding proteins in virulence of Streptococcus pneumoniae. Infect Immun (2000) 2.75
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect Immun (1997) 2.42
Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev (1993) 2.19
Multicenter evaluation of the Clostridium difficile TOX A/B TEST. J Clin Microbiol (1998) 2.09
Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.07
Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect Immun (1991) 1.87
Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol (2004) 1.73
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol (2004) 1.60
Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun (2000) 1.60
Specific detection of toxigenic strains of Clostridium difficile in stool specimens. J Clin Microbiol (1993) 1.52
The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile. J Clin Invest (1995) 1.51
Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42
Molecular identification of bacteria by fluorescence-based PCR-single-strand conformation polymorphism analysis of the 16S rRNA gene. J Clin Microbiol (1995) 1.38
Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun (1995) 1.35
Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun (1992) 1.32
Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR. J Clin Microbiol (2000) 1.28
Involvement of Ras-related Rho proteins in the mechanisms of action of Clostridium difficile toxin A and toxin B. Infect Immun (1995) 1.26
Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun (2011) 1.24
Nontoxigenic strains of Clostridium difficile lack the genes for both toxin A and toxin B. J Clin Microbiol (1991) 1.20
Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun (1999) 1.20
Rapid detection of toxigenic Clostridium difficile in fecal samples by magnetic immuno PCR assay. J Clin Microbiol (1994) 1.19
Positive regulation of Clostridium difficile toxins. Infect Immun (1997) 1.17
Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun (2001) 1.15
Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect Immun (1999) 1.09
Rapid and simple method for detecting the toxin B gene of Clostridium difficile in stool specimens by loop-mediated isothermal amplification. J Clin Microbiol (2005) 1.07
Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes. Infect Immun (1997) 1.07
Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother (1997) 1.07
Nutritional aspects of cytotoxin production by Clostridium difficile. Appl Environ Microbiol (1993) 0.96
Effects of Clostridium difficile toxin B on human monocytes and macrophages: possible relationship with cytoskeletal rearrangement. Infect Immun (1993) 0.90
Detection of toxB, a plasmid virulence gene of Escherichia coli O157, in enterohemorrhagic and enteropathogenic E. coli. J Clin Microbiol (2005) 0.89
The involvement of macrophage-derived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B. Immunology (1997) 0.87
Clinical significance of Clostridium difficile and its toxins in faeces of immunocompromised children. Gut (1994) 0.86
New method to generate enzymatically deficient Clostridium difficile toxin B as an antigen for immunization. Infect Immun (2000) 0.85
Clostridium difficile infection of the gut. J Clin Pathol (1996) 0.81
Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta. Infect Immun (1998) 0.80
Evaluation of a new enzyme immunoassay for Clostridium difficile toxin A. J Clin Pathol (1997) 0.80
Monoclonal antibodies specific for Clostridium difficile toxin B and their use in immunoassays. J Clin Microbiol (1992) 0.75
A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile. BMC Infect Dis (2016) 0.75
Cloning of fibA, encoding an immunogenic subunit of the fibril-like surface structure of Peptostreptococcus micros. J Bacteriol (1999) 0.75
Effects of anti-inflammatory drugs on fever and neutrophilia induced by Clostridium difficile toxin B. Mediators Inflamm (1996) 0.75
Macrofragment localization of the toxin A and toxin B genes of Clostridium difficile. Clin Diagn Lab Immunol (1996) 0.75
Cellular internalisation of bacterial toxins. Cytotechnology (1991) 0.75
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr (1980) 3.89
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol (1990) 1.65
Nucleotide sequence of Clostridium difficile toxin A. Nucleic Acids Res (1990) 1.55
Medium for use in antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1976) 9.38
Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria. Antimicrob Agents Chemother (1973) 9.35
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med (1997) 8.43
Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol (1977) 8.29
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med (1999) 7.81
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1979) 5.10
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Development of a micromethod for identification of anaerobic bacteria. Appl Microbiol (1975) 4.58
Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. Appl Environ Microbiol (1977) 4.09
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95
Differential characteristics of catalase-positive campylobacters correlated with DNA homology groups. Can J Microbiol (1984) 3.93
Micromethod for identification of anaerobic bacteria: design and operation of apparatus. Appl Microbiol (1975) 3.80
Deoxyribonucleic acid homology in bacterial taxonomy: effect of incubation temperature on reaction specificity. J Bacteriol (1968) 3.74
Cell wall composition and deoxyribonucleic acid similarities among the anaerobic coryneforms, classical propionibacteria, and strains of Arachnia propionica. J Bacteriol (1972) 3.43
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol (1982) 2.86
Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med (1988) 2.84
The pterin molybdenum cofactors. J Biol Chem (1992) 2.74
Arginine, a growth-limiting factor for Eubacterium lentum. J Bacteriol (1976) 2.67
Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65
Production by Salmonella typhimurium of 2,3-dihydroxybenzoylserine, and its stimulation of growth in human serum. J Infect Dis (1970) 2.62
Characterization of the molybdenum cofactor of sulfite oxidase, xanthine, oxidase, and nitrate reductase. Identification of a pteridine as a structural component. J Biol Chem (1980) 2.51
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Medium-dependent inhibition of Peptostreptococcus anaerobius by sodium polyanetholsulfonate in blood culture media. J Clin Microbiol (1976) 2.46
Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol (1985) 2.46
Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest (1998) 2.37
Nucleic acid homologies among oxidase-negative Moraxella species. J Bacteriol (1970) 2.35
Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS (2000) 2.32
Bidirectional effects of cytokines on the growth of Mycobacterium avium within human monocytes. J Immunol (1991) 2.29
Structural and metabolic relationship between the molybdenum cofactor and urothione. Proc Natl Acad Sci U S A (1982) 2.26
Taxonomy of the Clostridia: ribosomal ribonucleic acid homologies among the species. J Gen Microbiol (1975) 2.25
Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int J Antimicrob Agents (2004) 2.21
Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene (2001) 2.17
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 2.17
Serpulina pilosicoli sp. nov., the agent of porcine intestinal spirochetosis. Int J Syst Bacteriol (1996) 2.14
Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14
The enterotoxin of Bacteroides fragilis is a metalloprotease. Infect Immun (1995) 2.06
Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis (1999) 2.06
Paradoxical reactions in HIV and pulmonary TB. Chest (1998) 2.05
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00
The pterin component of the molybdenum cofactor. Structural characterization of two fluorescent derivatives. J Biol Chem (1984) 1.99
Purification and characterization of an enterotoxin from Bacteroides fragilis. Infect Immun (1992) 1.97
Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (1999) 1.94
Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol (1986) 1.92
Pulmonary function changes in children associated with fine particulate matter. Environ Res (1993) 1.91
DNA homology studies of the catalase-negative campylobacters and "Campylobacter fecalis," an emended description of Campylobacter sputorum, and proposal of the neotype strain of Campylobacter sputorum. Can J Microbiol (1985) 1.90
The toxigenic element of Clostridium difficile strain VPI 10463. Microb Pathog (1995) 1.89
Corynebacterium parvum: a synonym for Propionibacterium acnes? J Gen Microbiol (1974) 1.89
Differential effects of Clostridium difficile toxins on tissue-cultured cells. J Clin Microbiol (1982) 1.87
Resistance of some species of Clostridium to clindamycin. Antimicrob Agents Chemother (1973) 1.81
Effect of clavulanic Acid on anaerobic bacteria resistant to Beta-lactam antibiotics. Antimicrob Agents Chemother (1978) 1.78
In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis. Antimicrob Agents Chemother (1975) 1.78
Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem (1997) 1.77
Galactosamine glycan of Chondrococcus columnaris. Science (1966) 1.77
The abdominal compartment syndrome is a morbid complication of postinjury damage control surgery. Am J Surg (2001) 1.76
Phthalate esters as environmental contaminants. Nature (1972) 1.76
The effect of bacille Calmette-Guérin vaccination at birth on tuberculin skin test reactivity in Ugandan children. Int J Tuberc Lung Dis (1999) 1.76
Problems associated with counterimmunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol (1982) 1.75
A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.74
Structural features of multiple nifH-like sequences and very biased codon usage in nitrogenase genes of Clostridium pasteurianum. J Bacteriol (1986) 1.72
Mycobacterium africanum subtype II is associated with two distinct genotypes and is a major cause of human tuberculosis in Kampala, Uganda. J Clin Microbiol (2002) 1.72
Chemotherapy of an experimental Fusobacterium (Sphaerophorus) necrophorum infection in mice. Antimicrob Agents Chemother (1974) 1.71
Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med (1999) 1.67
Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol (1991) 1.67
Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology (1993) 1.67
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Fibrinolytic activity of oral anaerobic bacteria. Arch Oral Biol (1978) 1.65
Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol (1990) 1.65
Molecular basis of the biological function of molybdenum. Effect of tungsten on xanthine oxidase and sulfite oxidase in the rat. J Biol Chem (1974) 1.65
Members of the nuclear receptor superfamily regulate transcription from the hepatitis B virus nucleocapsid promoter. J Virol (1997) 1.64
Use of semisolid agar from initiation of pure Bacteroides fragilis infection in mice. Infect Immun (1976) 1.64
Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. Gastroenterology (1996) 1.63
Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol (2001) 1.63
Comparative study of six random oral spirochete isolates. Serological heterogeneity of Treponema denticola. J Periodontal Res (1985) 1.63
Inhibition of Bacteroides fragilis on blood agar plates and reversal of inhibition by added hemin. J Clin Microbiol (1976) 1.63
Beta-Lactamase activity in strains of Bacteroides melaninogenicus and Bacteroides oralis. Antimicrob Agents Chemother (1977) 1.62
Acetone, Isopropanol, and Butanol Production by Clostridium beijerinckii (syn. Clostridium butylicum) and Clostridium aurantibutyricum. Appl Environ Microbiol (1983) 1.62
Endemic selenium intoxication of humans in China. Am J Clin Nutr (1983) 1.61
Laminarinase (beta-glucanase) activity in Bacteroides from the human colon. Appl Environ Microbiol (1977) 1.61
The presence of five nifH-like sequences in Clostridium pasteurianum: sequence divergence and transcription properties. Nucleic Acids Res (1988) 1.60
Abdominal perfusion pressure: a superior parameter in the assessment of intra-abdominal hypertension. J Trauma (2000) 1.59
Proteolytic activity of the Bacteroides fragilis enterotoxin causes fluid secretion and intestinal damage in vivo. Infect Immun (1995) 1.59
Communicating cancer risk information: the challenges of uncertainty. Patient Educ Couns (1998) 1.58
Primate cytomegaloviruses encode and express an IL-10-like protein. Virology (2000) 1.58
Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun (1987) 1.57
Purification and characterization of Clostridium perfringens iota toxin: dependence on two nonlinked proteins for biological activity. Infect Immun (1986) 1.57
Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg (1994) 1.56
Ahomocysteinemia in molybdenum cofactor deficiency. Neurology (1998) 1.56